# Vinflunine

Source: https://onco.cc/drugs/vinflunine/  
OnCo record `vinflunine` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vinflunine (Javlor) is a chemotherapy infusion used in Europe as a second treatment for advanced bladder cancer after platinum chemotherapy has stopped working.

## Summary

Vinflunine was authorised by the European Commission in September 2009 as monotherapy for advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen, on a phase 3 trial of 370 patients against best supportive care in which median overall survival improved modestly, a statistically significant difference in the eligible population, making it the first drug with level 1 evidence in second-line urothelial cancer. It is not approved in the US, where the FDA declined the application. Pembrolizumab, enfortumab vedotin and erdafitinib have since displaced it in most guidelines, but it remains an option where immunotherapy is unsuitable. Neutropenia, constipation (prophylactic laxatives are recommended), fatigue and QT prolongation are the main adverse effects. Marketed by Pierre Fabre.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Tags: ema-list
- Brand: Javlor
- Modality: Fluorinated vinca alkaloid (microtubule inhibitor)
- Mechanism: Third-generation vinca alkaloid that binds tubulin with lower affinity than vinorelbine, suppressing microtubule dynamics and causing mitotic arrest; less neurotoxic than earlier vincas.
- Approvals: EU 2009: Advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a platinum-containing regimen

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Vinflunine
- EPAR (EMA): https://www.ema.europa.eu/en/medicines/human/EPAR/javlor

## Connected records

- drugs: [Vinblastine](https://onco.cc/drugs/vinblastine/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- companies: [Pierre Fabre](https://onco.cc/companies/pierre-fabre/)
- trials: [A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)](https://onco.cc/trials/nct07419295/)

---
JSON: https://onco.cc/api/v1/entities/vinflunine.json